趋化因子SDF-1a生物半衰期预测乳腺癌术后复发及转移  

Value of serum SDF-1a half-life in predicting postoperative recurrence and metastasis in patients of breast cancer

作　　者：吴高松[1] 马小鹏[1] 刘岩岩[1] 汪杰[1] 黄丽丽[1] 刘捷[1] 尹玉平[1] 易继林[1] 邹声泉[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院甲乳外科,武汉430030

出　　处：《中华普通外科杂志》2010年第11期907-909,共3页Chinese Journal of General Surgery

摘　　要：目的 探讨乳腺癌患者手术及化疗后血清趋化因子SDF-1a的动态变化,评价利用SDF-1a的半衰期（T1/2）预测乳腺癌术后复发及转移的价值.方法 回顾性分析112例同一医疗组收治的乳腺癌患者,分别检测乳腺癌改良根治术术前、术后以及每次化疗前1天的血清趋化因子SDF-1a的含量,观察治疗后SDF-1a的动态变化并计算其半衰期,分析其与乳腺癌治疗后复发、转移的相关性.结果 乳腺癌治疗后无复发转移组85例,手术以及化疗后血清SDF-1a逐渐下降至正常水平;而复发转移组27例SDF-1a下降缓慢,并维持在较高水平;复发转移组的SDF-1a半衰期较无复发转移组明显延长（P＜0.01）;取半衰期≥14 d预测乳腺癌治疗后复发转移的敏感性、特异性和准确度分别为81.5%、70.6%及73.2%.结论 乳腺癌治疗后血清SDF-1a的动态变化与肿瘤的复发转移密切相关.检测血清SDF-1a半衰期对于预测乳腺癌复发转移有临床价值.Objective To investigate the plasma level of SDF-1a in patients with breast cancer after modified radical mastectomy and chemotherapy, and to evaluate the value of serum SDF-1a half-life for predicting breast cancer recurrence and metastasis. The correlation of SDF-1 a half-life and breast cancer recurrence and metastasis after treatment were retrospectively analyzed. Methods Serum chemokine SDF-1a of 112 cases of breast cancer were detected before and after modified radical surgery, and 1 day beforeeach chemotherapy session. SDF-1a levels and the dynamic changes in the process were observed and calculated. Results In 85 cases with no recurrence and metastasis the plasma level of SDF-1 a decreased rapidly to normal level ,while that in 27 cases with recurrence and metastasis was on high level with the halflife of SDF-1a being longer than that in no recurrence group（P 〈0. 01 ）. Taking SDF-1a half-life ≥14 d as cut off point to predict breast cancer recurrence and metastasis after treatment, the sensitivity is 81.5%,specificity is 70. 6 %, and accuracy is 73.2%. Conclusions Serum SDF-1a half-life is a valuable marker in predicting postoperative breast cancer recurrence and metastasis.

关 键 词：乳腺肿瘤 半衰期 趋化因子类 

分 类 号：R686[医药卫生—骨科学]